2018 Journal for ImmunoTherapy of Cancer (JITC) Best Paper Awards

The JITC Best Paper Awards celebrate excellence in scientific research and are awarded to researchers demonstrating leadership in the field as well as innovation and high-quality execution and discussion in their manuscripts. Papers published in the last 12 months authored by SITC members were eligible for nomination for these awards.

JITC Best Basic Science Paper

Articles nominated in this category present innovative research in basic medical sciences that have a direct relevance to future research in clinical medicine.

Weir_Genevieve2.jpgPatrick Danaher, PhD

NanoString Technologies

“Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)”

Patrick Danaher, PhD; Sarah Warren, PhD; Rongze Lu, PhD; Josue Samayoa, PhD; Amy Sullivan, BS; Irena Pekker, PhD; Brett Wallden, MS; Francesco M. Marincola, MD and Alessandra Cesano, MD, PhD

Journal for ImmunoTherapy of Cancer 2018, 6:63 (22 June 2018)

JITC Best Clinical/Translational Paper

Papers in this category present clinical research that has a clear potential to optimize patient care, with particular emphasis on high quality randomized controlled trials, novel combination treatments, therapies, novel diagnostic or prognostic insights and new insights into mechanism of action.


Howard L. Kaufman, MD, FACS

Replimune Group

“Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials”

Howard L. Kaufman, MD, FACS; Robert H. I. Andtbacka, MD, CM, FACS, FRCSC; Frances A. Collichio, MD; Michael Wolf, MS; Zhongyun Zhao, PhD; Mark Shilkrut, MD, PhD; Igor Puzanov, MD, MSCI, FACP and Merrick Ross, MD

Journal for ImmunoTherapy of Cancer 2017, 5:72 (19 September 2017)